RMTIHealthcare · Drug Manufacturers - Specialty & GenericThe 2 Wall Street analysts covering Rockwell Medical, Inc. hold a median 12-month price target of $20 — +146.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Rockwell Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RMTI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +146.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $20 |
| 30 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 11 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | $9.00 |
| 4 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | $9.00 |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Oct 2023 | Maxim Group | Initiates | Buy | — |
| 4 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Sept 2023 | HC Wainwright& Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 July 2023 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RMTI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 84% of US stocks
Cheaper than 77% of US stocks
Cheaper than 83% of US stocks
Higher than 54% of US stocks
Higher than 27% of US stocks
Higher than 17% of US stocks
Higher than 27% of US stocks
Higher than 22% of US stocks
Higher than 33% of US stocks
Higher than 32% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rockwell Medical, Inc. has a market value of $32.6M and an enterprise value of $21.8M.
Revenue in the twelve months to 31 Mar 2026: $67.7M. The latest quarter grew 10.6% year on year.
Net income over the same four quarters: −$5.4M, a −8.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.50.
Free cash flow in the twelve months to 31 Mar 2026: $1.8M, after $729K of capital spending.
Trailing P/E: −5.3×; forward P/E: 115.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Rockwell Medical, Inc. employs 157 people — $431K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rockwell Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rockwell Medical, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and operational performance for the quarter.
Why it matters — Earnings calls provide investors and analysts with direct insight into the company's financial health, strategic direction, and management's perspective on recent performance.
Rockwell Medical reported a Q2 loss of $0.34 per share, wider than the Zacks Consensus Estimate of a $0.17 loss but narrower than the $0.50 per-share loss from a year ago. The company also lagged revenue estimates for the quarter.
Why it matters — An RMTI watcher would care because the wider-than-expected quarterly loss and revenue miss signal that the company's results fell short of analyst expectations for the period.
Rockwell Medical announced its second quarter 2026 results for Wixom, Michigan, reporting strong year-over-year growth, an expanding gross margin, and positive operating cash flow.
Why it matters — RMTI watchers would care because the quarter reflects strengthening financial performance, including growth, margin expansion, and positive cash flow.
Zacks reports that Rockwell Medical (RMTI) may post negative earnings in its upcoming report, noting the company lacks the combination of key ingredients typically associated with a likely earnings beat. The piece advises investors to prepare for the release by reviewing key expectations.
Why it matters — RMTI investors would care because the item points to a potentially unfavorable earnings outcome ahead of the company's upcoming report.
The 2 Wall Street analysts covering Rockwell Medical, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Rockwell Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rockwell Medical, Inc. 49 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Rockwell Medical, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +146.9% from the last close, and Ticker Nerd's factor model ranks Rockwell Medical, Inc. 49 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rockwell Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
Rockwell Medical, Inc. is a healthcare company specializing in products for patients undergoing hemodialysis treatment.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript". Rockwell Medical, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and operational performance for the quarter.
Rockwell Medical, Inc. is a healthcare company specializing in products for patients undergoing hemodialysis treatment. The company focuses on developing, manufacturing, commercializing, and distributing a broad portfolio of hemodialysis concentrates and related supplies used by dialysis providers worldwide. Its offering includes acid and bicarbonate concentrates in liquid, dry, and cartridge forms, along with ancillary products such as cleaning solutions and water treatment supplies that support safe and efficient dialysis operations. Rockwell Medical serves in-center and home dialysis providers, including large national networks and independent clinics, through multi-year product purchase agreements and distribution relationships. Headquartered in Wixom, Michigan, Rockwell Medical plays a significant role in the U.S. dialysis supply chain as a major supplier of hemodialysis concentrates, helping clinics maintain consistent access to essential life-sustaining therapies for patients with end-stage renal disease and chronic kidney conditions.
CEO Dr. Mark Strobeck Ph.D. · 157 employees · United States · https://www.rockwellmed.com